Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Sees Large Volume Increase - What's Next?

Key Points

• Shares of Damora Therapeutics (NASDAQ:DMRA) experienced a huge volume spike to 1,288,843 shares traded (a 456% increase), with the stock last quoted at $25.02.
• Several firms (Guggenheim, UBS, Evercore, RBC) have issued buy/outperform ratings and MarketBeat's consensus is a Moderate Buy with a target price of $43.40.
• Damora is a clinical‑stage biotech developing galectin‑3 inhibitors (lead programs GB0139 inhaled and GB1211 oral) and has a market cap of about $1.51 billion.

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) saw strong trading volume on Thursday . 1,288,843 shares traded hands during trading, an increase of 456% from the previous session's volume of 231,617 shares.The stock last traded at $25.02 and had previously closed at $24.69.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Guggenheim restated a "buy" rating and set a $40.00 target price (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. UBS Group began coverage on Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. They set a "buy" rating and a $45.00 price target on the stock. Evercore began coverage on Damora Therapeutics, Inc. Common Stock in a research report on Wednesday, March 25th. They set an "outperform" rating and a $46.00 price target on the stock. Zacks Research raised Damora Therapeutics, Inc. Common Stock to a "hold" rating in a research report on Friday, January 9th. Finally, Royal Bank Of Canada began coverage on Damora Therapeutics, Inc. Common Stock in a research report on Friday, April 24th. They set an "outperform" rating and a $40.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $43.40.

Damora Therapeutics, Inc. Common Stock Stock Performance

The stock has a 50-day moving average of $26.42 and a 200-day moving average of $23.40. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -2.07 and a beta of 1.50.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC acquired a new stake in Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at approximately $40,000. Geode Capital Management LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at $266,000. Virtu Financial LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth approximately $49,000. Sigma Planning Corp acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $334,000. Finally, Two Sigma Investments LP acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth approximately $76,000. Institutional investors and hedge funds own 14.20% of the company's stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company's research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.